Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Senzer

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 26, 2016
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's SarcomaMaurizio Ghisoli, Minal Barve, Robert Mennel, et al.
Genes|April 8, 2014
Notch1 activation up-regulates pancreatic and duodenal homeobox-1Shi-He Liu, Guisheng Zhou, Juehua Yu, et al.
Gynecologic Oncology Reports|June 7, 2021
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648]Jonathan Oh, Minal Barve, Neil Senzer, et al.
Gynecologic Oncology Reports|December 28, 2020
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenanceJohnathan Oh, Minal Barve, Neil Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccineJairo Olivares, Padmasini Kumar, Yang Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerJohn Nemunaitis, Irene Eiseman, Casey Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2004
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumorsNeil Senzer, Sridhar Mani, Alexander Rosemurgy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastasesJohn H Suh, Baldassarre Stea, Abdenour Nabid, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 27, 2015
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory CancerMinal Barve, Zhaohui Wang, Padmasini Kumar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I studyC Casey Cunningham, Sunil Chada, James A Merritt, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 26, 2016
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's SarcomaMaurizio Ghisoli, Minal Barve, Robert Mennel, et al.
Genes|April 8, 2014
Notch1 activation up-regulates pancreatic and duodenal homeobox-1Shi-He Liu, Guisheng Zhou, Juehua Yu, et al.
Gynecologic Oncology Reports|June 7, 2021
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648]Jonathan Oh, Minal Barve, Neil Senzer, et al.
Gynecologic Oncology Reports|December 28, 2020
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenanceJohnathan Oh, Minal Barve, Neil Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccineJairo Olivares, Padmasini Kumar, Yang Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerJohn Nemunaitis, Irene Eiseman, Casey Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2004
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumorsNeil Senzer, Sridhar Mani, Alexander Rosemurgy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastasesJohn H Suh, Baldassarre Stea, Abdenour Nabid, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 27, 2015
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory CancerMinal Barve, Zhaohui Wang, Padmasini Kumar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I studyC Casey Cunningham, Sunil Chada, James A Merritt, et al.
Pageof 8